• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    3/9/21 9:40:26 PM ET
    $ERYP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ERYP alert in real time by email
    SC 13G 1 sc13g07422eryp_03092021.htm THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    ERYTECH Pharma S.A.

     (Name of Issuer)

    Ordinary Shares, nominal value €0.10 per share

     (Title of Class of Securities)

    29604W108

     (CUSIP Number)

    March 8, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,144,331 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              2,144,331 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,144,331 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            10.1% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    (1) Includes 310,194 American Depositary Shares (“ADSs”), each of which represents one (1) Share (as defined below).

    2

    CUSIP No. 29604W108

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,144,331 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              2,144,331 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,144,331 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            10.1% (1)  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    (1) Includes 310,194 ADSs, each of which represents one (1) Share.

    3

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,579,621 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              1,579,621 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,579,621 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.5% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    (1) Includes 198,372 ADSs, each of which represents one (1) Share.

    4

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,579,621 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              1,579,621 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,579,621 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.5% (1)  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    (1) Includes 198,372 ADSs, each of which represents one (1) Share.

    5

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         260,060 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              260,060 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            260,060 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.2% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    (1) Includes 53,195 ADSs, each of which represents one (1) Share.

    6

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         260,060 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              260,060 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            260,060 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.2% (1)  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    (1) Includes 53,195 ADSs, each of which represents one (1) Share.

    7

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,723,952 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,723,952 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,723,952 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            17.6% (1)  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    (1) Includes 508,566 ADSs, each of which represents one (1) Share.

    8

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         4,081,941 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              4,081,941 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,081,941 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            19.3% (1)  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    (1) Includes 625,000 ADSs, each of which represents one (1) Share.

    9

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         4,081,941 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              4,081,941 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,081,941 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            19.3% (1)  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    (1) Includes 625,000 ADSs, each of which represents one (1) Share.

    10

    CUSIP No. 29604W108

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         4,081,941 (1)  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              4,081,941 (1)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,081,941 (1)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            19.3% (1)  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    (1) Includes 625,000 ADSs, each of which represents one (1) Share.

    11

    CUSIP No. 29604W108

    Item 1(a).Name of Issuer:

    ERYTECH Pharma S.A., a French corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Bâtiment Adénine

    60 Avenue Rockefeller

    69008 Lyon France

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

    12

    CUSIP No. 29604W108

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares, nominal value €0.10 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    29604W108

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    13

    CUSIP No. 29604W108

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on March 9, 2021, (i) BVF beneficially owned 2,144,331 Shares, including 310,194 ADSs, (ii) BVF2 beneficially owned 1,579,621 Shares, including 198,372 ADSs and (iii) Trading Fund OS beneficially owned 260,060 Shares, including 53,195 ADSs.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 2,144,331 Shares beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,579,621 Shares beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 260,060 Shares beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,723,952 Shares beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 4,081,941 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and those certain Partners managed accounts (the “Partners Managed Accounts”), including 97,929 Shares, including 63,239 ADSs held in the Partners Managed Accounts.

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 4,081,941 Shares beneficially owned by Partners.

     

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 4,081,941 Shares beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    14

    CUSIP No. 29604W108

     

    (b)Percent of class:

     

    The following percentages are based on 21,139,668 Shares outstanding as of February 28, 2021, which is the total number of Shares outstanding as disclosed in a press release by the Issuer on March 8, 2021.

     

    As of the close of business on March 9, 2021, (i) BVF beneficially owned approximately 10.1% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 7.5% of the outstanding Shares, (iii) Trading Fund OS beneficially owned approximately 1.2% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 10.1% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 7.5% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own approximately 1.2% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 17.6% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 19.3% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Accounts).

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and the Partners Managed Accounts.

    15

    CUSIP No. 29604W108

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    16

    CUSIP No. 29604W108

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: March 9, 2021

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC., its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President      

     

    17

    Get the next $ERYP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ERYP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ERYP
    Leadership Updates

    Live Leadership Updates

    See more
    • ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023

               ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy           Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio

      6/23/23 4:30:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ERYP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023

               ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy           Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio

      6/23/23 4:30:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

      ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (NASDAQ:ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech. As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capit

      6/20/23 4:05:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

      ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the "Autorité des Marchés Financiers" (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities an

      4/28/22 4:05:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ERYP
    SEC Filings

    See more
    • SEC Form 6-K filed by Erytech Pharma S.A.

      6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

      1/19/24 10:04:34 AM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Erytech Pharma S.A.

      6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

      11/16/23 7:41:44 AM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Erytech Pharma S.A.

      6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)

      10/25/23 9:21:10 AM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ERYP
    Financials

    Live finance-specific insights

    See more
    • ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

      ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28, 2022 – ERYTECH Pharma (NASDAQ:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the "Autorité des Marchés Financiers" (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities an

      4/28/22 4:05:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

      ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)Once registered, parti

      9/15/21 4:05:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ERYP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Erytech Pharma S.A. (Amendment)

      SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)

      2/14/23 12:41:00 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Erytech Pharma S.A. (Amendment)

      SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)

      12/23/22 5:08:10 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Erytech Pharma S.A. (Amendment)

      SC 13G/A - Erytech Pharma S.A. (0001624422) (Subject)

      2/14/22 1:49:20 PM ET
      $ERYP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care